陕西美邦药业集团股份有限公司股票交易异常波动公告

Core Viewpoint - The stock of Shaanxi Meibang Pharmaceutical Group Co., Ltd. has experienced significant price fluctuations, with a cumulative increase of over 20% in three consecutive trading days, raising concerns about potential irrational market behavior and the disconnect between stock price and company performance [2][4]. Group 1: Stock Performance and Market Behavior - The company's stock price increased by 46.43% from February 10 to February 24, 2026, while the Shanghai Composite Index decreased by 0.27% during the same period [2][9]. - The stock's recent performance is significantly higher than the industry index and the Shanghai Composite Index, indicating potential market overreaction [2][9]. - The company's latest rolling price-to-earnings (P/E) ratio is 143.19, which is substantially higher than the industry average P/E ratio of 33.99, suggesting a bubble in the stock price [3][9]. Group 2: Company Financial Performance - For the first three quarters of 2025, the company reported a revenue of 609 million yuan, a year-on-year decrease of 2.23%, and a net profit attributable to shareholders of 36.1961 million yuan, down 16.36% year-on-year [10]. - The company's operational activities are reported to be normal, with no significant changes in the external environment [5]. Group 3: Disclosure and Compliance - The company has confirmed that there are no undisclosed significant matters that could affect stock trading, including major asset restructuring or business collaborations [6][11]. - The company has not identified any media reports or market rumors that could significantly impact its stock price [7].